HiLo: Multicentre randomised phase III clinical trial of high versus low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation following surgery for differentiated thyroid cancer
- Registry ID
- EUCTR2005-003687-37
- Source registry
- EUCTR
- Status
- GB - no longer in EU/EEA
- Phase
- PHASE3
- Sponsor
- University College London
- Start date
- 2006-06-21
- Last update
- 2026-08-16
Conditions
- Differentiated thyroid cancer (DTC)
Summary
The main objectives of the trial are: (i) to determine whether a low dose of radioactive iodine (1.1 GBq) is as effective as the commonly used high dose (3.7GBq) in ablating any remaining thyroid tissue after surgery (ii) to determine whether taking recombinant human thyroid stimulating hormone (rhTSH) has no adverse effect on radioactive iodine ablation of the thyroid remnant compared to the current practice of withdrawing thyroid hormone 2−4 weeks before radioiodine ablation.
Locations
View on source registry